CLAIMS

1. Use of an antibody or binding fragment thereof that specifically binds to human interleukin-6 receptor (IL-6R) in the manufacture of a medicament for treating rheumatoid arthritis in a subject who was previously ineffectively treated for rheumatoid arthritis by administration of methotrexate, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL) wherein the VH comprises three complementarity determining regions (CDRs) found within the sequence of SEQ ID NO:2 and the VL comprises three CDRs found within the sequence of SEQ ID NO:3, wherein the antibody or binding fragment thereof is formulated to be administered to the subject at a dose of between 150 and 200 mg every two weeks.

2. The use of claim 1, wherein the antibody or binding fragment thereof is formulated to be administered at a dose of 150 mg every two weeks.

3. The use of claim 1, wherein the antibody or binding fragment thereof is formulated to be administered at a dose of 200 mg every two weeks.

4. The use of any one of claims 1-3, wherein the subject achieves at least a 20% improvement in the American College of Rheumatology (ACR) core set disease index after at least 12 weeks of treatment.

5. The use of any one of claims 1-3, wherein the subject achieves at least a 20% improvement in the American College of Rheumatology (ACR) core set disease index after at least 24 weeks of treatment.

6. The use of any one of claims 1-3, wherein the subject achieves at least a 50% improvement in the American College of Rheumatology (ACR) core set disease index after at least 12 weeks of treatment.

7. The use of any one of claims 1-3 wherein the subject achieves at least a 70% improvement in the American College of Rheumatology (ACR) core set disease index after at least 12 weeks of treatment.

8. The use of any one of claims 1 to 7, wherein the methotrexate is to be administered at a dose of between 6 and 25 mg per week.

9. The use of any one of claims 1 to 8, wherein the antibody or binding fragment thereof is sarilumab or binding fragment thereof.

10. The use of any one of claims 1 to 9, wherein the antibody or binding fragment thereof is formulated to be administered subcutaneously to the subject.

11. The use of any one of claims 1-10, wherein the antibody or binding fragment thereof and the methotrexate are to be administered concurrently.

12. The use of any one of claims 1-10, wherein the antibody or binding fragment thereof and the methotrexate are to be administered sequentially.

13. The use of any one of claims 1 to 12, wherein the antibody or binding fragment thereof is the antibody.

14. The use of any one of claims 1 to 13, wherein the VH comprises the sequence of SEQ ID NO:2 and the VL comprises the sequence of SEQ ID NO:3.

15. The use of claim 13, wherein the antibody is sarilumab.